EGB Ventures is a physician-led venture formation family office focused on creating, financing and developing biotechnology companies built around clinically validated therapeutic opportunities.
EGB Ventures is a venture formation family office dedicated to creating, financing and developing innovative biotechnology companies addressing significant unmet medical needs.
Unlike traditional venture capital firms, EGB Ventures takes an active role in company creation — identifying promising scientific assets, structuring companies around those opportunities, recruiting experienced management teams, and supporting strategic execution through key development milestones.
We identify breakthrough science, build companies around it, and accelerate the development of therapies that can change lives.
We identify therapeutically compelling opportunities supported by strong biological rationale, translational evidence and meaningful clinical validation. By focusing on data-supported science, we seek to reduce development risk while advancing therapies with the potential to address significant unmet medical needs.
We actively form biotechnology companies around promising scientific opportunities. Our team helps structure new ventures, recruit experienced leadership teams, guide development strategy, and support financing initiatives designed to position companies for long-term growth and value creation.
We focus on serious diseases where patients have limited or no effective treatment options. By combining scientific insight, disciplined development planning, and strategic company building, we seek to accelerate the advancement of therapies that can meaningfully improve patient outcomes while generating long-term shareholder value.
Led by physician and biotechnology executive William Garner, EGB Ventures evaluates opportunities through both a clinical and financial lens. This perspective helps identify therapeutically compelling assets supported by meaningful scientific rationale and clinical validation.
We believe the most successful companies are built around meaningful patient benefit. Every program we support aims to significantly improve patient outcomes, from better efficacy and safety to enhanced quality of life and access to treatment.
Our team has founded, financed, and operated successful pharmaceutical ventures from pre-clinical stages through to late-stage clinical development and commercial partnerships. We know the path, and the pitfalls, and we bring that experience to every company we build.
We leverage a broad global ecosystem of scientists, clinical leaders, academia, investors and strategic partners. These connections enable access to breakthrough science, world-leading advisors, and high-quality capital to accelerate development at every stage.
